Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 201

Sort by

Sort Order Select

Journal Articles

Anti-Leukemic Activity of Single Agent Venetoclax in Newly Diagnosed Acute Myeloid Leukemia: A Sub-Set Analysis of the Caveat Study

Chong Chyn Chua, MBBS, John Reynolds, PhD, Jessica M Salmon, PhD, Chun Fong, Stephen B Ting, MB BS, FRACP, FRCPA, PhD, Ing Soo Tiong, MBBS,FRACP,FRCPA, Shaun Fleming, MBBS,, Sarah MacRaild, Donia M Moujalled, PhD, Giovanna Pomilio, Nik Cummings, Julie McManus, Adam Ivey, BSc, MSc, PhD, Purvi M Kakadia, PhD, Stefan K. Bohlander, MD, Andrew W. Roberts, MBBS, PhD FRACP, FRCPA, Andrew H. Wei, PhD FRACP, FRCPA, MBBS

Blood (2019) 134 (Supplement_1): 462.

https://doi.org/10.1182/blood-2019-126640

Published: 2019

Journal Articles

Efficacy of OR21, a Novel Oral Demethylating Agent in Chronic Myeloid Leukemia

Kazuharu Kamachi, MD, Hiroshi Ureshino, MD, Nao Yoshida, MD, Yuki Kurahashi, Tatsuro Watanabe, PhD, Seiji Okada, MD PhD, Shinya Kimura, MD PhD

Blood (2019) 134 (Supplement_1): 5365.

https://doi.org/10.1182/blood-2019-125460

Published: 2019

Journal Articles

Phase I Dose Escalation Study of Radiotherapy and Durvalumab (MEDI4736) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): The RaDD Study

Eliza A Hawkes, Kate Manos, Geoff Chong, Jodie Palmer, Michael MacManus, Colm Keane, MD, Andrew Scott, Jake Shortt, MBBS FRACP FRCPA PhD, David Ritchie, MD PhD, Leonid Churilov, Laura Johnston, Tom Witkowski, Allison Barraclough, Sze-Ting Lee, Wendi Lin, Rachel Koldej, Richard Khor

Blood (2019) 134 (Supplement_1): 5328.

https://doi.org/10.1182/blood-2019-122635

Published: 2019

Journal Articles

Targeting DNA Damage and Repair in Acute Myeloid Leukemia Carrying Internal Tandem Duplication of Fms-like Tyrosine Kinase 3 (FLT3-ITD) - a Mechanistic Study

Ka Lam Nelson Ng, PhD, Claire Lynn, Thomas Wing Yan Leung, Eric Chi Wai So, PhD, Anskar Yu Hung Leung, MD PhD

Blood (2019) 134 (Supplement_1): 1261.

https://doi.org/10.1182/blood-2019-129472

Published: 2019

Journal Articles

Impact of Post-Transplant Consolidative Radiotherapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma and a PET-CT Based Predictive Model for Relapse

Collin Chin, MBBS, Andrew Wirth, MBBS, MD FRACP, FRANZCR, David Ritchie, MD PhD, Michael Hofman, MBBS (Hons), FRACP, FAANMS, Michael MacManus, John F. Seymour, MBBS, PhD FRACP, Belinda Campbell, MBBS, MMed, FRANZCR, Michael Dickinson, MBBS,FRACP,FRCPA

Blood (2019) 134 (Supplement_1): 4044.

https://doi.org/10.1182/blood-2019-122716

Published: 2019

Journal Articles

Regulation of Platelet Function By Adenosine Receptors

Daniel N. Darlington, PhD, Xiaowu Wu, MD MSc, Kevin L. Chang, BS, James Bynum, PhD, Andrew P. Cap, MD PhD

Blood (2019) 134 (Supplement_1): 2348.

https://doi.org/10.1182/blood-2019-131129

Published: 2019

Journal Articles

Treatment Outcome and a Practical 10-Point Prognostic Index in Adult Patients with Non-M3 Acute Myeloid Leukemia: A Retrospective, Multicenter Study in Malaysia

Tze Shin Leong, MBBS,MRCP,MSc, Sen Mui Tan, Lee Ping Chew, Tee Chuan Ong, Siew Lian Chong, Kar Ying Yong, Siong Leng Hon, Syazarin Fidhora Nasution, Ching Tiong Ko, Vanusha Devaraja, Andy Sing Ong Tang, Tsen Chuen Jerome Tan, Ngee Siang Lau, Sharifah Shahnaz Syed Abd Kadir, Veena Selvaratnam, Yee Yee Yap, Bee Sun Lee, William Kian Boon Law, Jameela Sathar

Blood (2019) 134 (Supplement_1): 2606.

https://doi.org/10.1182/blood-2019-126656

Published: 2019

Journal Articles

The MEK Inhibitor Trametinib Enhances Diverse T Cell Reconstitution with Suppressing Xenogeneic Graft-Versus-Host-Disease

Hidekazu Itamura, MD PhD, Hiroyuki Muranushi, MD, Takero Shindo, MD PhD, Kazutaka Kitaura, DVM, PhD, Seiji Okada, MD PhD, Tadasu Shin-I, PhD, Ryuji Suzuki, DVM, PhD, Akifumi Takaori-Kondo, MD PhD, Shinya Kimura, MD PhD

Blood (2019) 134 (Supplement_1): 1929.

https://doi.org/10.1182/blood-2019-128913

Published: 2019

Journal Articles

Dissecting the Immune Cell Progeny of CAR-Expressing Hematopoietic Stem Cells in a Humanized Mouse Model

Heng-Yi Liu, Nezia Rahman, Tzu-Ting Chiou, PhD, Satiro N. De Oliveira, MD

Blood (2019) 134 (Supplement_1): 4640.

https://doi.org/10.1182/blood-2019-129746

Published: 2019

Journal Articles

A Prognostic Model Integrating PET-Derived Quantitative Parameters and Image Texture Analyses Using Radiomics in a Large Prospective Phase III Trial, GOYA

Lale Kostakoglu, MD MPH, Paola Berchialla, PhD, Federico Dalmasso, PhD, Larry A Pierce, PhD, Umberto Vitolo, Maurizio Martelli, MD, Laurie H Sehn, MD, Marek Trněný, MD, Tina G Nielsen, MD PhD, Christopher R Bolen, PhD, Deniz Sahin, BSc, Calvin Lee, MD, Tarec Christoffer C. El-Galaly, MD, Federico Mattiello, PhD, Paul E Kinahan, PhD, Stephane Chauvie, PhD

Blood (2019) 134 (Supplement_1): 883.

https://doi.org/10.1182/blood-2019-123450

Published: 2019

Journal Articles

Lentiviral Gene Therapy with Autologous Hematopoietic Stem and Progenitor Cells (HSPCs) for the Treatment of Severe Combined Immune Deficiency Due to Adenosine Deaminase Deficiency (ADA-SCID): Results in an Expanded Cohort

Blood (2019) 134 (Supplement_1): 3345.

https://doi.org/10.1182/blood-2019-123432

Published: 2019

Journal Articles

Tocilizumab to Prevent Infusion-Related Events in Patients with Chronic Lymphocytic Leukemia and Co-Morbidities Treated with Obinutuzumab and Chlorambucil: Results from the Randomized Phase Ib GALACTA Trial

Ciara Louise Freeman, MRCP, MSc, FRCPath, MBBChir, Sebastian Böttcher, Javier De la Serna, Julio Delgado, Franca Falzetti, Marco Gobbi, MD, Sandra Lejniece, Maria Chiara Di Bernardo, Navita L Mallalieu, Tina Nielsen, Andrea Knapp, John G. Gribben

Blood (2018) 132 (Supplement 1): 4419.

https://doi.org/10.1182/blood-2018-99-118238

Published: 2018

Journal Articles

Long Term Outcomes of Venetoclax Therapy for Complex Karyotype Relapsed/Refractory Chronic Lymphocytic Leukemia

Thomas Lew, MBBS, Mary Ann Anderson, FRACP, FRCPA, MBBS, Constantine S. Tam, MBBS, MD FRACP, FRCPA, Sasanka Handunnetti, MBBS, Dennis Carney, Meaghan Wall, MBBS, Andrew W. Roberts, MBBS, PhD, John F. Seymour, MBBS, PhD

Blood (2018) 132 (Supplement 1): 4431.

https://doi.org/10.1182/blood-2018-99-113905

Published: 2018

Journal Articles

A Phase I/II, First in Human Trial of the Bruton's Tyrosine Kinase Inhibitor M7583 in Patients with B-Cell Malignancies

Wojciech Jurczak, Simon Rule, MD, William Townsend, MD FRCPath, David Tucker, Barbara Sarholz, Jürgen Scheele, John G. Gribben, Pier Luigi Zinzani, MD

Blood (2018) 132 (Supplement 1): 4161.

https://doi.org/10.1182/blood-2018-99-112808

Published: 2018

Journal Articles

Exhausted CLL T Cells Mediated By PD1 Expression an Important Mechanism for CD19 CAR Efficacy in CLL in the Adoptive Transfer TCL1 Mouse Model

Robin Sanderson, MRCP, FRCPath, Arantxa Romero-Toledo, MSc, John G. Gribben

Blood (2018) 132 (Supplement 1): 4537.

https://doi.org/10.1182/blood-2018-99-111180

Published: 2018

Journal Articles

AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R 2 ) Vs Rituximab/Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Blood (2018) 132 (Supplement 1): 445.

https://doi.org/10.1182/blood-2018-99-110861

Published: 2018

Journal Articles

Interim Results from an Ongoing Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Blood (2018) 132 (Supplement 1): 4196.

https://doi.org/10.1182/blood-2018-99-113411

Published: 2018

Journal Articles

Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia

Piers Blombery, MBBS, Mary Ann Anderson, FRACP, FRCPA, MBBS, Jianan Gong, PhD, Rachel Thijssen, Richard W Birkinshaw, PhD, Ella Thompson, PhD, Charis E Teh, PhD, Tamia Nguyen, Zhen Xu, PhD, Christoffer Flensburg, PhD, Thomas Lew, MBBS, Ian Majewski, PhD, Daniel Gray, David Alan Westerman, MBBS, FRCPA, FRACP, Constantine S. Tam, MBBS (Hons), MD FRACP, FRCPA, John F. Seymour, MBBS, PhD, Peter E Czabotar, PhD, David Huang, Andrew W. Roberts, MBBS, PhD

Blood (2018) 132 (Supplement 1): LBA-7.

https://doi.org/10.1182/blood-2018-120761

Published: 2018

Journal Articles

Ibrutinib + Obinutuzumab Versus Chlorambucil + Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results from Phase 3 iLLUMINATE

Carol Moreno, MD PhD, Richard Greil, MD, Fatih Demirkan, MD, Alessandra Tedeschi, MD, Bertrand Anz, MD, Loree Larratt, MD, Martin Simkovic, MD PhD, Olga Samoilova, MD, Jan Novak, MD PhD, Dina Ben-Yehuda, MD, Vladimir Strugov, MD, Devinder Gill, MD MRCP, FRCPath, John G. Gribben, Emily Hsu, PhD, Cathy Zhou, MS, Fong Clow, ScD, Danelle F. James, MD MAS, Lori Styles, MD, Ian W. Flinn, MD PhD

Blood (2018) 132 (Supplement 1): 691.

https://doi.org/10.1182/blood-2018-99-111370

Published: 2018

Journal Articles

Extracellular Vesicles: Overview and Clinical Implications

Francoise Dignat-George

Blood (2018) 132 (Supplement 1): SCI-25.

https://doi.org/10.1182/blood-2018-99-109472

Published: 2018

NARROW

Anti-Leukemic Activity of Single Agent Venetoclax in Newly Diagnosed Acute Myeloid Leukemia: A Sub-Set Analysis of the Caveat Study

Efficacy of OR21, a Novel Oral Demethylating Agent in Chronic Myeloid Leukemia

Phase I Dose Escalation Study of Radiotherapy and Durvalumab (MEDI4736) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): The RaDD Study

Targeting DNA Damage and Repair in Acute Myeloid Leukemia Carrying Internal Tandem Duplication of Fms-like Tyrosine Kinase 3 (FLT3-ITD) - a Mechanistic Study

Impact of Post-Transplant Consolidative Radiotherapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma and a PET-CT Based Predictive Model for Relapse

Regulation of Platelet Function By Adenosine Receptors

Treatment Outcome and a Practical 10-Point Prognostic Index in Adult Patients with Non-M3 Acute Myeloid Leukemia: A Retrospective, Multicenter Study in Malaysia

The MEK Inhibitor Trametinib Enhances Diverse T Cell Reconstitution with Suppressing Xenogeneic Graft-Versus-Host-Disease

Dissecting the Immune Cell Progeny of CAR-Expressing Hematopoietic Stem Cells in a Humanized Mouse Model

A Prognostic Model Integrating PET-Derived Quantitative Parameters and Image Texture Analyses Using Radiomics in a Large Prospective Phase III Trial, GOYA

Lentiviral Gene Therapy with Autologous Hematopoietic Stem and Progenitor Cells (HSPCs) for the Treatment of Severe Combined Immune Deficiency Due to Adenosine Deaminase Deficiency (ADA-SCID): Results in an Expanded Cohort

Tocilizumab to Prevent Infusion-Related Events in Patients with Chronic Lymphocytic Leukemia and Co-Morbidities Treated with Obinutuzumab and Chlorambucil: Results from the Randomized Phase Ib GALACTA Trial

Long Term Outcomes of Venetoclax Therapy for Complex Karyotype Relapsed/Refractory Chronic Lymphocytic Leukemia

A Phase I/II, First in Human Trial of the Bruton's Tyrosine Kinase Inhibitor M7583 in Patients with B-Cell Malignancies

Exhausted CLL T Cells Mediated By PD1 Expression an Important Mechanism for CD19 CAR Efficacy in CLL in the Adoptive Transfer TCL1 Mouse Model

AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R 2 ) Vs Rituximab/Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Interim Results from an Ongoing Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia

Ibrutinib + Obinutuzumab Versus Chlorambucil + Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results from Phase 3 iLLUMINATE

Extracellular Vesicles: Overview and Clinical Implications

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only